ConductScience.org, home

Paper40977752

JAK Inhibitors for Treatment of VEXAS Syndrome: A Systematic Review of 186 Cases.

Bahramian S and 9 others. Dermatol Res Pract, 2025. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. JAK Inhibitors for Treatment of VEXAS Syndrome: A Systematic Review of 186 Cases. Papers, record 40977752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40977752

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
JAK Inhibitors for Treatment of VEXAS Syndrome: A Systematic Review of 186 Cases.
PubMed
Journal
Dermatol Res Pract
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
2.36, provisional
iCite
Revised in PubMed
2025-09-24
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bahramian SSaeed
2Fazeli PPatrickhttps://orcid.org/0000-0003-4394-8929
3Rafati AArezou
4Demokri SSardar
5Memari HHuriahttps://orcid.org/0000-0003-0104-5350
6Soheili AAmirali
7Esmaeili FFarzadhttps://orcid.org/0000-0002-2265-9995
8Pourmehdi Ardebili MMohammad
9Erfani HHaniye
10Vahabi SMSeyed Mohammadhttps://orcid.org/0000-0003-4736-6803

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References53

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135597594Acute tubulointerstitial nephritis revealing VEXAS syndrome.Kidney Int2022https://conductscience.org/library/papers/35597594PubMed
236641501Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.Int J Hematol2023https://conductscience.org/library/papers/36641501PubMed
338736269Safety and efficacy of tofacitinib in 97 alopecia areata patients.J Cosmet Dermatol2024https://conductscience.org/library/papers/38736269PubMed
440046741Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry.Front Pharmacol2025https://conductscience.org/library/papers/40046741PubMed
526432019UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration.Trends Mol Med2015https://conductscience.org/library/papers/26432019PubMed
640183135The Challenging and Unique Diagnosis of VEXAS Syndrome: A Case Report.J Investig Med High Impact Case Rep2025https://conductscience.org/library/papers/40183135PubMed
738398362VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge.J Clin Med2024https://conductscience.org/library/papers/38398362PubMed
840412417Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study.Lancet Rheumatol2025https://conductscience.org/library/papers/40412417PubMed
938333211Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort.Front Immunol2024https://conductscience.org/library/papers/38333211PubMed
1037247942JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.Ann Rheum Dis2023https://conductscience.org/library/papers/37247942PubMed
1134611997VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis.Arthritis Rheumatol2022https://conductscience.org/library/papers/34611997PubMed
1237337622Tofacitinib as a biologic response modifier in VEXAS syndrome: A case series.Int J Rheum Dis2023https://conductscience.org/library/papers/37337622PubMed
1340373272Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX.Blood2025https://conductscience.org/library/papers/40373272PubMed
1437606963Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome.Rheumatology (Oxford)2024https://conductscience.org/library/papers/37606963PubMed
1536150749Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.Ann Rheum Dis2023https://conductscience.org/library/papers/36150749PubMed
1639081801Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome.Hemasphere2024https://conductscience.org/library/papers/39081801PubMed
1735230710Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a presentation of two cases with dermatologic findings.Int J Dermatol2023https://conductscience.org/library/papers/35230710PubMed
1837230920JAK-STAT pathway inhibitors in dermatology.An Bras Dermatol2023https://conductscience.org/library/papers/37230920PubMed
1938473222JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature.Cancers (Basel)2024https://conductscience.org/library/papers/38473222PubMed
2033782057The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.BMJ2021https://conductscience.org/library/papers/33782057PubMed

See all 53 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42547647JAK inhibitor therapy in CANDLE syndrome: a systematic review of clinical outcomes in 46 patients.Eur J Pediatr2026https://conductscience.org/library/papers/42547647PubMed
42472066JAK Inhibitors for Treatment of Pyoderma Gangrenosum and Sweet Syndrome: A Systematic Review of Published Case Reports.Dermatol Res Pract2026https://conductscience.org/library/papers/42472066PubMed
42200825VEXAS Syndrome: Clinical Features, Hematologic Involvement, and Clinical Outcomes of Current and Emerging Therapies.Hematol Rep2026https://conductscience.org/library/papers/42200825PubMed
41953903Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature.Health Sci Rep2026https://conductscience.org/library/papers/41953903PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40977752

GET https://conductscience.org/api/papers/v1/40977752/references?page=2